it's time

While the sp has dropped today on over 3.4 million shares traded, the market has still increased the value of the company, compared to the last capital raising, by 45%.

Why?

1. Because given the insight provided by the EMA minutes approval will happen soon after the end of the FY.

2. Any concern over inventory is minor since it isn't certain that a shelf life extension won't be granted and even if new stock is required a capital raising was going to be necessary to advance the FDA trials.

3. Once approval has been received there will be no problem raising the capital.